Acute Coronary Syndrome is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Acute Coronary Syndrome have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Acute Coronary Syndrome compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Acute Coronary Syndrome overview
Acute coronary syndrome (ACS) encompasses ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina, constituting a subset of coronary heart disease (CHD) responsible for a third of deaths in individuals over 35. Unlike some asymptomatic forms of CHD, ACS is always symptomatic. Diagnosis begins with an ECG, crucial for distinguishing between STEMI, NSTEMI, and unstable angina. Initial ACS treatment involves aspirin (300 mg), heparin bolus, and intravenous (IV) heparin infusion, barring contraindications. Antiplatelet therapy with ticagrelor or clopidogrel is also advised, forming essential components of the comprehensive ACS management protocol.
For a complete picture of PTSR and LoA scores for drugs in Acute Coronary Syndrome, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
